Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating immunotherapy in combination with Axitinib for advanced collecting duct carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Collecting Duct Carcinoma

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Collecting Duct Carcinoma | Phase 2 | Status: RECRUITING